A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.
What Are The Drugs Involved
The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.
The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.
These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.
What Could This Mean For Bowel Cancer Treatment In The Future
The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.
All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.
Credit: iStock
One of the most effective ways to prevent rabies deaths could be by vaccinating dogs rather than just people before they are bitten. A new study published in The Lancet Regional Health – Southeast Asia modelled different strategies in Kerala for eradicating human rabies deaths between 2026 and 2035.
The study found that mass vaccination of dogs could bring the annual rabies deaths among people in Kerala close to zero within about three years even if 70% of the dog population were vaccinated.
On the other hand, vaccinating children before exposure to rabies was projected to prevent relatively few additional deaths at substantially higher cost.
India carries one of the worst largest rabies burdens. That's why the study could point towards a feasible and practical solution to eradicate the deadly infection.
Most human rabies deaths in India are linked to bites from infected dogs. This means that the disease can be tackled at its source by reducing transmission among dogs.
India records an estimated 9.1 million animal bites every year, with more than three-quarters caused by dogs. A 2024 estimate from the Indian Council of Medical Research's National Institute of Epidemiology estimates India's annual human rabies deaths to be about 5,726, which is an alarming public health issue.
The study puts emphasis on the fact that vaccinating a person after a bite protects that individual, whereas, vaccinating dogs reduces the probability that an infected dog will transmit rabies to many people in the first place.
Researchers from the University of Glasgow, Kerala's health and animal-husbandry departments, Kerala University of Health Sciences and the London School of Economics and Political Science used mathematical modelling to compare different strategies to combat rabies in Kerala.
One strategy was routine pre-exposure prophylaxis (PrEP) for children. Another focused on mass dog vaccination, while the model also considered improvements to post-exposure prophylaxis (PEP), the treatment given after a potentially rabid bite.
The researchers found that adding routine childhood PrEP provided minimal additional protection, preventing fewer than 10 deaths on average over a decade, while costing considerably more than strategies focused on controlling rabies transmission among dogs.
The model estimated that achieving 70% vaccination coverage among dogs could reduce annual human rabies deaths in Kerala to near zero within approximately three years.
Also read: Abhayrab Rabies Vaccine Batch Found Misbranded, ‘Not Of Standard Quality’: DCGI Alerts States
One of the study's striking findings was about the size of Kerala's stray-dog population. The researchers' modelling suggested that the state's actual stray-dog population could be around five times higher than official census estimates.
If vaccination programmes are based on an underestimated dog population, authorities could believe they have reached adequate coverage while a large proportion of dogs remain unvaccinated. That creates what epidemiologists call an immunity gap, allowing rabies transmission to continue.
Additionally, dog vaccination does not make human post-exposure treatment unnecessary. If a person is bitten or scratched by an animal that could have rabies, the wound should be washed thoroughly with soap and running water and medical care should be sought immediately.
Depending on the exposure, PEP can include rabies vaccine and rabies immunoglobulin (RIG). This is particularly important because rabies becomes extremely difficult to treat once symptoms begin.
The study also found that improving timely access to PEP could prevent more deaths than expanding routine pre-exposure vaccination of children.
Credit: AI
The US Food and Drug Administration (FDA) is investigating an outbreak of Salmonella Bovismorbificans infections in multiple states. According to reports, the at least infection cases are being linked to recalled broccoli sprouts across four states, including two hospitalisations. The outbreak hasn't resulted in any casualties yet.
The outbreak has been linked to broccoli sprouts grown by Evergreen Fresh Sprouts, LLC, based in Moyie Springs, Idaho. The FDA and the US Centers for Disease Control and Prevention (CDC) are investigating the outbreak with state and local health authorities.
The FDA has issued a clear warning: “Do not eat, serve, or sell recalled broccoli sprouts grown by Evergreen Fresh Sprouts, LLC.”
Also read: Granola Marketed For Nursing Mothers In US Recalled Over Potential Salmonella Contamination
According to the FDA, illnesses began between July 7 and August 26, 2026. Out of the 19 infected people who were interviewed by investigators, all 19 reported eating sprouts, while 17 specifically reported eating broccoli sprouts. That epidemiological pattern helped investigators identify sprouts as the likely driver of the infection.
Traceback investigations by the FDA and state partners then identified Evergreen Fresh Sprouts as the common grower of broccoli sprouts eaten by patients before they became sick.
On September 4, the company initiated a recall after Montana state officials found Salmonella in a sample of its broccoli sprout. Whole-genome sequencing showed that the Salmonella found in the product was the same strain causing illnesses in the outbreak.
The recalled products were sold in plastic bags or plastic clamshell containers and have expiration dates of September 7, 9, 11, 14 or 16, 2026.
Distribution has been confirmed in Idaho, Montana and Washington, although the FDA said the products may have reached additional states. The 22 cases are from Idaho, Montana, Utah and Washington.
Also read: Cyclospora to Alzheimer’s: Trump Administration Scales Back Key Health Research
Salmonella is a group of bacteria that can cause salmonellosis, a gastrointestinal infection usually acquired by consuming contaminated food or water.
Symptoms typically begin 12 to 72 hours after exposure and can include diarrhoea, fever and abdominal cramps. Most people recover within four to seven days without specific treatment, but some infections can become severe.
Young children, older adults and people with weakened immune systems are at greater risk of serious complications from the infection. In severe cases, Salmonella can cause dehydration or allow the bacteria to enter the bloodstream, potentially leading to invasive infection and complications affecting other organs.
Sprouts are grown in warm, moist conditions, which help seeds germinate but can also provide favourable conditions for bacterial growth.
The seeds themselves can become contaminated before sprouting. Once bacteria are present, the warm and humid environment used to produce sprouts can allow them to multiply. Since sprouts are often eaten raw, there may be no cooking step to eliminate the bacteria.
The current FDA investigation involves broccoli sprouts, and it is separate from another ongoing US investigation involving Salmonella and E. coli infections linked to alfalfa sprouts.
Consumers, restaurants and retailers should not eat, sell or serve the recalled Evergreen Fresh Sprouts broccoli sprouts.
The FDA also advises people who purchased or received the recalled product to carefully clean and sanitise surfaces and containers that may have come into contact with the sprouts. This is important because Salmonella can spread through cross-contamination.
Anyone who develops symptoms resembling Salmonella infection after eating the recalled sprouts should contact a healthcare provider.
Credit: X.com
Col Anurag Upadhyay, a former Indian Army officer and Special Forces veteran, is living with locked-in syndrome, a rare neurological condition in which a person can remain conscious and aware while losing the ability to speak and move most muscles.
While there is currently no medicine or injection proven to reverse established locked-in syndrome, experts stress the importance of specialized neurorehabilitation, communication aids and appropriate assistive technologies.
A decorated Army officer and Special Forces veteran, Col Upadhyay suffered a severe posterior circulation stroke in August 2025. The stroke reportedly caused extensive neurological damage and left him with locked-in syndrome.
Despite being unable to move or speak normally, Col Upadhyay is conscious and aware. According to a social media post seeking medical and rehabilitation support for him, he communicates complete thoughts through eye movements and an alphabet-based scanning system.
Cleveland Clinic defines the syndrome as "a rare and serious neurological disorder that causes complete paralysis of all voluntary muscles except for the eyes, while leaving the person fully conscious and aware"
“Locked-in syndrome is one of the most devastating neurological conditions,” said Dr Sudhir Kumar, neurologist at Apollo Hospitals, Hyderabad, in a post on social media platform X.
The condition can leave a person unable to speak or move most muscles despite remaining conscious and aware.
It can severely affect communication and physical independence. However, the extent of impairment and potential for recovery can vary depending on the cause, location and severity of the brain injury, as well as whether the syndrome is complete or incomplete.
Dr Kumar said, “The honest answer is: There is currently no medicine or injection proven to reverse established locked-in syndrome.”
However, the absence of a proven medicine does not mean that supportive treatment and rehabilitation have no role.
Even after 13 months, Dr Kumar strongly recommended assessment at a specialised centre with experience in long-term neurorehabilitation and assistive technology.
Dr Kumar recommended a detailed reassessment by a multidisciplinary team that could include a neurologist, rehabilitation physician, physiotherapist, occupational therapist, speech and swallowing therapist, respiratory therapist, psychologist and specialist nurses.
Such an assessment can help identify even small voluntary movements that may have been missed or may have emerged over time.
He also recommended intensive, individualised neurorehabilitation focused on maintaining joint mobility, preventing contractures, improving head and trunk control, increasing sitting tolerance and supporting any residual voluntary movement.
“Even a small movement of a finger, thumb, head or eye can sometimes become functionally very important,” Dr Kumar said.
For people with locked-in syndrome, establishing a reliable way to communicate can be particularly important.
Dr Kumar stressed that “communication should be a top priority” and recommended considering an eye-gaze or eye-tracking communication system where appropriate.
“Restoring a reliable means of communication can dramatically improve autonomy and quality of life,” he said.
Dr Kumar also suggested “periodic reassessment of swallowing and bulbar function” and “speech-language therapy”, along with “chest physiotherapy, respiratory exercises, secretion management and periodic reassessment of ventilatory requirements”.
Emphasising the importance of mental health and quality of life, he said, “Never assume that a person with locked-in syndrome does not understand what is happening around them.”
Dr Kumar also highlighted “exciting ongoing research” into several technologies that could potentially improve communication, interaction and rehabilitation for people with severe paralysis.
These include:
However, these technologies should not be presented as established treatments for locked-in syndrome.
“These technologies are promising, but it is important to be realistic: most are not yet proven treatments capable of reliably reversing locked-in syndrome,” Dr Kumar said.
For people living with locked-in syndrome, continued access to evidence-based rehabilitation, communication tools, assistive technologies and specialised care can remain important.
“For a man who has served our country, we owe him continued care, respect and access to every evidence-based opportunity for rehabilitation,” Dr Kumar said.
“There may not be a miracle medicine today. But there is still meaningful medicine to be practiced and meaningful hope to be offered.”
© $2026 Times Horizon Private Limited